Market Overview

UPDATE: Citigroup Reiterates Illumina at Neutral on Valuation

Share:
Related ILMN
Biotech Short-Sellers Prefer Amgen To Gilead Sciences
Benzinga's Top Upgrades

Citigroup maintained Illumina (NASDAQ: ILMN) at Neutral with a $51 price target.

Citigroup commented, "We expect the stock to be under pressure today as investors question the deal valuation/near-term $0.20 EPS dilution of the Verinata deal, the longer term impact of ILMN competing with its own customers (i.e., SQNM), and the level (if any) of Roche takeout premium to still ascribe to the stock. We remain on the sidelines on ILMN stock given the stock's current multiple and level of investment required/EPS power for the company in 2013."

Illumina closed at $54.76 on Friday.

Latest Ratings for ILMN

DateFirmActionFromTo
May 2015Morgan StanleyUpgradesEqual-weightOverweight
Apr 2015Tigress FinancialUpgradesBuyStrong Buy
Apr 2015CitigroupMaintainsBuy

View More Analyst Ratings for ILMN
View the Latest Analyst Ratings

Posted-In: CitigroupAnalyst Color Reiteration Intraday Update Analyst Ratings

 

Related Articles (ILMN)

Around the Web, We're Loving...

Get Benzinga's Newsletters